

11/98, an antigen isolated from *Eimeria necatrix* MCK01, and an antigen isolated from *Eimeria necatrix* ARI-MEDNEC₃+8, and (b) a veterinarily acceptable carrier or excipient.

2. (Amended) The vaccine according to claim 1 which further comprises at least one unattenuated *Eimeria* strain.

3. (Amended) The vaccine according to claim 1 wherein said vaccine comprises *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, and *E. tenella* ARI-11/98, and said vaccine further comprises at least one of *E. necatrix* MCK01 and *E. necatrix* ARI-MEDNEC₃+8.

4. (Amended) The vaccine according to claim 3 wherein said vaccine further comprises a vaccine strain of *Eimeria brunetti*, a vaccine strain of *Eimeria mitis* and a vaccine strain of *Eimeria praecox*.

5. (Amended) The vaccine according to claim 1 wherein said vaccine further comprises a vaccine against a poultry disease other than one caused by said components.

6. (Amended) The vaccine according to claim 5 wherein said vaccine further comprises a vaccine component effective in providing protection against infection by one or more members selected from the group consisting of Marek's disease, mycoplasma and salmonella.

7. (Amended) An *Eimeria* strain selected from the group consisting of *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, *E. tenella* ARI-11/98, *E. necatrix* MCK01 and *E. necatrix* ARI-MEDNEC₃+8.

8. (Amended) The vaccine according to claim 1 wherein said vaccine comprises a component that is in the form of a whole and/or fractured sporulated oocyst or sporocyst.

9. (Amended) The vaccine according to claim 8 wherein said vaccine comprises 15 to 500 sporulated oocysts per dose.

10. (Amended) The *Eimeria* strain according to claim 7 wherein said *Eimeria* strain is in the form of an oocyst or a sporulated oocyst.
